Grace Therapeutics, Inc.
NASDAQ: GRCE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Prashant Kohli
- Employees
- 4
- Headquarters
- Princeton, United States
- IPO year
- 2012
- Market cap
- $37.9M
- Website
- https://www.acastipharma.com
Loading GRCE…
Loading profile data…Frequently asked questions about GRCE
What does Grace Therapeutics, Inc. (GRCE) do?
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipelin...
Where does GRCE trade?
Grace Therapeutics, Inc. (GRCE) trades on the NASDAQ Global Market.
What sector is GRCE in?
Grace Therapeutics, Inc. (GRCE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Grace Therapeutics, Inc.?
Prashant Kohli is the chief executive officer of Grace Therapeutics, Inc. (GRCE).
Where is Grace Therapeutics, Inc. headquartered?
Grace Therapeutics, Inc. is headquartered in United States.
Does GRCE pay a dividend?
Grace Therapeutics, Inc. (GRCE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GRCE go public?
Grace Therapeutics, Inc. (GRCE) completed its initial public offering in 2012.